Data on a new treatment approach utilizing bispecific monoclonal antibodies targetting B-cell maturation antigen (BCMA) were recently published, yielding very encouraging results in the setting of relapsed and/or refractory multiple myeloma (RRMM). How to safely and effectively deliver this treatment to patients and where it fits in the RRMM treatment paradigm are important questions for the future.

中文翻译：

---

当财富的尴尬还不够时


最近发表了利用针对 B 细胞成熟抗原 (BCMA) 的双特异性单克隆抗体的新治疗方法的数据，在复发和/或难治性多发性骨髓瘤 (RRMM) 的治疗中取得了非常令人鼓舞的结果。如何安全有效地向患者提供这种治疗以及它在 RRMM 治疗范式中的适用位置是未来的重要问题。